{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T04:16:04Z","timestamp":1780546564879,"version":"3.54.1"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,1,6]],"date-time":"2017-01-06T00:00:00Z","timestamp":1483660800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs R D"],"published-print":{"date-parts":[[2017,3]]},"DOI":"10.1007\/s40268-016-0167-3","type":"journal-article","created":{"date-parts":[[2017,1,6]],"date-time":"2017-01-06T09:25:33Z","timestamp":1483694733000},"page":"199-210","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Identification of a Syndrome Class of Neuropsychiatric Adverse Reactions to Mefloquine from Latent Class Modeling of FDA Adverse Event Reporting System Data"],"prefix":"10.1007","volume":"17","author":[{"given":"Remington L.","family":"Nevin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeannie-Marie","family":"Leoutsakos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,1,6]]},"reference":[{"key":"167_CR1","unstructured":"World Health Organization. Central nervous system reactions related to the antimalarial drug, mefloquine. WHO\/MAL\/89\/1054. 1989. Available from: http:\/\/whqlibdoc.who.int\/malaria\/WHO_MAL_89.1054.pdf . Accessed 5 Sep 2016."},{"key":"167_CR2","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s40120-016-0045-5","volume":"5","author":"RL Nevin","year":"2016","unstructured":"Nevin RL, Byrd AM. Neuropsychiatric adverse reactions to mefloquine: a systematic comparison of prescribing and patient safety guidance in the US, UK, Ireland, Australia, New Zealand, and Canada. Neurol Ther. 2016;5:69\u201383.","journal-title":"Neurol Ther."},{"key":"167_CR3","unstructured":"US Food and Drug Administration. FDA drug safety communication: FDA approves label changes for antimalarial drug mefloquine hydrochloride due to risk of serious psychiatric and nerve side effects. July 29, 2013. Available from: http:\/\/www.fda.gov\/downloads\/Drugs\/DrugSafety\/UCM362232.pdf . Accessed 5 Sep 2016."},{"key":"167_CR4","doi-asserted-by":"crossref","first-page":"225","DOI":"10.2310\/7060.2000.00069","volume":"7","author":"P Schlagenhauf","year":"2000","unstructured":"Schlagenhauf P, Steffen R. Neuropsychiatric events and travel: do antimalarials play a role? J Travel Med. 2000;7:225\u20136.","journal-title":"J Travel Med."},{"key":"167_CR5","doi-asserted-by":"crossref","first-page":"260106","DOI":"10.1155\/2015\/260106","volume":"2015","author":"RL Nevin","year":"2015","unstructured":"Nevin RL. Rational risk-benefit decision-making in the setting of military mefloquine policy. J Parasitol Res. 2015;2015:260106.","journal-title":"J Parasitol Res."},{"key":"167_CR6","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/S0140-6736(05)64522-9","volume":"348","author":"S Clift","year":"1996","unstructured":"Clift S, Grabowski P. Malaria prophylaxis and the media. Lancet. 1996;348:344.","journal-title":"Lancet."},{"key":"167_CR7","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1186\/s12936-016-1391-6","volume":"15","author":"RL Nevin","year":"2016","unstructured":"Nevin RL, Croft AM. Psychiatric effects of malaria and anti-malarial drugs: historical and modern perspectives. Malar J. 2016;15:332.","journal-title":"Malar J."},{"key":"167_CR8","doi-asserted-by":"crossref","first-page":"963","DOI":"10.7326\/0003-4819-126-12-199706150-00006","volume":"126","author":"C Ohrt","year":"1997","unstructured":"Ohrt C, Richie TL, Widjaja H, et al. Mefloquine compared with doxycycline for the prophylaxis of malaria in Indonesian soldiers: a randomized, double-blind, placebo-controlled trial. Ann Intern Med. 1997;126:963\u201372.","journal-title":"Ann Intern Med."},{"key":"167_CR9","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1086\/322694","volume":"33","author":"D Overbosch","year":"2001","unstructured":"Overbosch D, Schilthuis H, Bienzle U, et al. Atovaquone-proguanil versus mefloquine for malaria prophylaxis in nonimmune travelers: results from a randomized, double-blind study. Clin Infect Dis. 2001;33:1015\u201321.","journal-title":"Clin Infect Dis."},{"key":"167_CR10","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S0002-9343(96)90011-X","volume":"100","author":"MR Wallace","year":"1996","unstructured":"Wallace MR, Sharp TW, Smoak B, et al. Malaria among United States troops in Somalia. Am J Med. 1996;100:49\u201355.","journal-title":"Am J Med."},{"key":"167_CR11","first-page":"257","volume":"44","author":"E Boudreau","year":"1993","unstructured":"Boudreau E, Schuster B, Sanchez J, et al. Tolerability of prophylactic Lariam regimens. Trop Med Parasitol. 1993;44:257\u201365.","journal-title":"Trop Med Parasitol."},{"key":"167_CR12","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1001\/jama.1991.03460030067030","volume":"265","author":"HO Lobel","year":"1991","unstructured":"Lobel HO, Bernard KW, Williams SL, et al. Effectiveness and tolerance of long-term malaria prophylaxis with mefloquine: need for a better dosing regimen. JAMA. 1991;265:361\u20134.","journal-title":"JAMA."},{"key":"167_CR13","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s40800-016-0030-z","volume":"3","author":"J Livezey","year":"2016","unstructured":"Livezey J, Oliver T, Cantilena L. Prolonged neuropsychiatric symptoms in a military service member exposed to mefloquine. Drug Saf Case Rep. 2016;3:7.","journal-title":"Drug Saf Case Rep."},{"key":"167_CR14","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.tmaid.2012.03.006","volume":"10","author":"RL Nevin","year":"2012","unstructured":"Nevin RL. Limbic encephalopathy and central vestibulopathy caused by mefloquine: a case report. Travel Med Infect Dis. 2012;10:144\u201351.","journal-title":"Travel Med Infect Dis."},{"key":"167_CR15","first-page":"350417","volume":"2011","author":"AL Peterson","year":"2011","unstructured":"Peterson AL, Seegmiller RA, Schindler LS. Severe neuropsychiatric reaction in a deployed military member after prophylactic mefloquine. Case Rep Psychiatry. 2011;2011:350417.","journal-title":"Case Rep Psychiatry."},{"key":"167_CR16","doi-asserted-by":"crossref","unstructured":"Levin A. FDA warning highlights mefloquine\u2019s mental health risks. In: Psychiatric News, September 10, 2013. Available from: http:\/\/psychnews.psychiatryonline.org\/doi\/10.1176\/appi.pn.2013.9a25 . Accessed 5 Sep 2016.","DOI":"10.1176\/appi.pn.2013.9a25"},{"key":"167_CR17","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/978-3-319-22985-0_19","volume-title":"Posttraumatic stress disorder and related disorders in Combat Veterans","author":"RL Nevin","year":"2015","unstructured":"Nevin RL, Ritchie E. The mefloquine intoxication syndrome: a significant potential confounder in the diagnosis and management of PTSD and other chronic deployment-related neuropsychiatric disorders. In: Ritchie EC, editor. Posttraumatic stress disorder and related disorders in Combat Veterans. Cham: Springer; 2015. p. 257\u201378."},{"key":"167_CR18","first-page":"224","volume":"41","author":"EC Ritchie","year":"2013","unstructured":"Ritchie EC, Block J, Nevin RL. Psychiatric side effects of mefloquine: applications to forensic psychiatry. J Am Acad Psychiatry Law. 2013;41:224\u201335.","journal-title":"J Am Acad Psychiatry Law."},{"key":"167_CR19","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1080\/10705510701575396","volume":"14","author":"KL Nylund","year":"2007","unstructured":"Nylund KL, Asparouhov T, Muth\u00e9n BO. Deciding on the number of classes in latent class analysis and growth mixture modeling: a Monte Carlo simulation study. Struct Equ Model. 2007;14:535\u201369.","journal-title":"Struct Equ Model."},{"key":"167_CR20","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1176\/ajp.151.5.650","volume":"151","author":"SV Faraone","year":"1994","unstructured":"Faraone SV, Tsuang MT. Measuring diagnostic accuracy in the absence of a \u201cgold standard\u201d. Am J Psychiatry. 1994;151:650\u20137.","journal-title":"Am J Psychiatry."},{"key":"167_CR21","doi-asserted-by":"crossref","first-page":"109","DOI":"10.2165\/00002018-199920020-00002","volume":"20","author":"EG Brown","year":"1999","unstructured":"Brown EG, Wood L, Wood S. The medical dictionary for regulatory activities (MedDRA). Drug Saf. 1999;20:109\u201317.","journal-title":"Drug Saf."},{"key":"167_CR22","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/0035-9203(91)90005-J","volume":"85","author":"R Steffen","year":"1991","unstructured":"Steffen R. Travel medicine: prevention based on epidemiological data. Trans R Soc Trop Med Hyg. 1991;85:156\u201362.","journal-title":"Trans R Soc Trop Med Hyg."},{"key":"167_CR23","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1001\/archinte.167.16.1752","volume":"167","author":"TJ Moore","year":"2007","unstructured":"Moore TJ, Cohen MR, Furberg CD. Serious adverse drug events reported to the Food and Drug Administration, 1998\u20132005. Arch Intern Med. 2007;167:1752\u20139.","journal-title":"Arch Intern Med."},{"key":"167_CR24","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1080\/01621459.1997.10473658","volume":"92","author":"K Bandeen-Roche","year":"1997","unstructured":"Bandeen-Roche K, Miglioretti DL, Zeger SL, Rathouz PJ. Latent variable regression for multiple discrete outcomes. J Am Stat Assoc. 1997;92:1375\u201386.","journal-title":"J Am Stat Assoc."},{"key":"167_CR25","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1093\/pan\/mpq025","volume":"18","author":"JK Vermunt","year":"2010","unstructured":"Vermunt JK. Latent class modeling with covariates: two improved three-step approaches. Polit Anal. 2010;18:450\u201369.","journal-title":"Polit Anal."},{"key":"167_CR26","first-page":"209","volume":"17","author":"J Bernard","year":"1989","unstructured":"Bernard J, Le Camus J, Sarrouy J, et al. Toxic encephalopathy induced by mefloquine: 3 case reports. Med Armees. 1989;17:209\u201311.","journal-title":"Med Armees."},{"key":"167_CR27","first-page":"1654","volume":"16","author":"J Bernard","year":"1987","unstructured":"Bernard J, Le Camus J, Sarrouy J, et al. Toxic encephalopathy caused by mefloquine? Presse Med. 1987;16:1654\u20135.","journal-title":"Presse Med."},{"key":"167_CR28","doi-asserted-by":"crossref","first-page":"577","DOI":"10.7326\/0003-4819-110-7-577","volume":"110","author":"B Rouveix","year":"1989","unstructured":"Rouveix B, Bricaire F, Michon C, et al. Mefloquine and an acute brain syndrome. Ann Intern Med. 1989;110:577\u20138.","journal-title":"Ann Intern Med."},{"key":"167_CR29","first-page":"776","volume":"18","author":"J Lapras","year":"1989","unstructured":"Lapras J, Vighetto A, Trillet M, Garin JP. Transient disorders of memory after a malaria attack: caused by mefloquine? Press Med. 1989;18:776.","journal-title":"Press Med."},{"key":"167_CR30","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/S0140-6736(89)93029-8","volume":"2","author":"A Bj\u00f6rkman","year":"1989","unstructured":"Bj\u00f6rkman A. Acute psychosis following mefloquine prophylaxis. Lancet. 1989;2:865.","journal-title":"Lancet."},{"key":"167_CR31","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1056\/NEJM198911163212017","volume":"321","author":"LC Patchen","year":"1989","unstructured":"Patchen LC, Campbell CC, Williams SB. Neurologic reactions after a therapeutic dose of mefloquine. N Engl J Med. 1989;321:1415\u20136.","journal-title":"N Engl J Med."},{"key":"167_CR32","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.tmaid.2014.10.021","volume":"13","author":"\u00c5 Ringqvist","year":"2015","unstructured":"Ringqvist \u00c5, Bech P, Glenth\u00f8j B, Petersen E. Acute and long-term psychiatric side effects of mefloquine: a follow-up on Danish adverse event reports. Travel Med Infect Dis. 2015;13:80\u20138.","journal-title":"Travel Med Infect Dis."},{"key":"167_CR33","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1046\/j.1365-2125.2003.02035.x","volume":"57","author":"MM Riemsdijk van","year":"2004","unstructured":"van Riemsdijk MM, Sturkenboom MCJM, Ditters JM, et al. Low body mass index is associated with an increased risk of neuropsychiatric adverse events and concentration impairment in women on mefloquine. Br J Clin Pharmacol. 2004;57:506\u201312.","journal-title":"Br J Clin Pharmacol."},{"key":"167_CR34","doi-asserted-by":"crossref","first-page":"199","DOI":"10.4088\/JCP.v66n0207","volume":"66","author":"MM Riemsdijk van","year":"2005","unstructured":"van Riemsdijk MM, Sturkenboom MCJM, Pepplinkhuizen L, Stricker BHC. Mefloquine increases the risk of serious psychiatric events during travel abroad: a nationwide case\u2013control study in the Netherlands. J Clin Psychiatry. 2005;66:199\u2013204.","journal-title":"J Clin Psychiatry."},{"key":"167_CR35","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1097\/MJT.0b013e318262316f","volume":"21","author":"KA Getz","year":"2012","unstructured":"Getz KA, Stergiopoulos S, Kaitin KI. Evaluating the completeness and accuracy of MedWatch data. Am J Ther. 2012;21:442\u20136.","journal-title":"Am J Ther."},{"key":"167_CR36","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1001\/jamainternmed.2015.3565","volume":"175","author":"P Ma","year":"2015","unstructured":"Ma P, Marinovic I, Karaca-Mandic P. Drug manufacturers\u2019 delayed disclosure of serious and unexpected adverse events to the US Food and Drug Administration. JAMA Intern Med. 2015;175:1565\u20136.","journal-title":"JAMA Intern Med."}],"container-title":["Drugs in R&D"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40268-016-0167-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40268-016-0167-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40268-016-0167-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,25]],"date-time":"2017-06-25T03:29:39Z","timestamp":1498361379000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40268-016-0167-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1,6]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,3]]}},"alternative-id":["167"],"URL":"https:\/\/doi.org\/10.1007\/s40268-016-0167-3","relation":{},"ISSN":["1174-5886","1179-6901"],"issn-type":[{"value":"1174-5886","type":"print"},{"value":"1179-6901","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,1,6]]}}}